(Q36677345)

English

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

scientific article published on 5 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

6 references

17 June 2019

27 September 2019

27 November 2019

13 December 2019

14 November 2020

1 May 2021

0 references

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

0 references

Crohn's disease

0 references

monoclonal antibody

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

disease-modifying antirheumatic drug

1 reference

14 November 2020

rheumatoid arthritis

0 references

1 reference

1 May 2021

psoriatic arthritis

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

author name string

Gerd R Burmester

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Remo Panaccione

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kenneth B Gordon

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Melissa J McIlraith

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Ana P M Lacerda

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

5 May 2012

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 April 2013

6 references

17 June 2019

27 September 2019

27 November 2019

13 December 2019

14 November 2020

1 May 2021

Annals of the Rheumatic Diseases

7 references

Europe PubMed Central

PMC publication ID

15 August 2017

17 June 2019

27 September 2019

27 November 2019

13 December 2019

14 November 2020

1 May 2021

72

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

517-524

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

copyright license

Creative Commons Attribution-NonCommercial

6 references

17 June 2019

27 September 2019

27 November 2019

13 December 2019

14 November 2020

1 May 2021

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Vascular effects of biologic agents in RA and spondyloarthropathies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Adalimumab safety in global clinical trials of patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Melanoma epidemiology and trends.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Cancer incidence before and after kidney transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Predictors of infection in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

30 September 2017

Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

28 June 2018

Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

28 June 2018

Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

28 June 2018

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595151

5 September 2018

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of psoriasis after B cell depletion with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra

1 reference

https://pubmed.ncbi.nlm.nih.gov/22562972

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2011-201244

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36677345&oldid=1645814685"